Inactive Instrument

AgeX Therapeutics, Inc. Stock price

Equities

AGE

US00848H2076

Delayed Nyse 04:10:00 2024-03-26 pm EDT 5-day change 1st Jan Change
11.1 USD -11.90% Intraday chart for AgeX Therapeutics, Inc. -16.48% -18.02%
Dynamic Chart
Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction. CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee CI
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023 CI
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology MT
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000 MT
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company CI
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction. CI
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000 MT
AgeX Therapeutics, Inc. Announces CEO Changes CI
Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee CI
AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation MT
AgeX Therapeutics, Inc. announced that it has received $13.66 million in funding from Juvenescence Ltd. CI
More news
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The Company's proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock AgeX Therapeutics, Inc. - Nyse